Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin 16.5% - Octapharma

Next Previous
Drug Profile

Immune globulin 16.5% - Octapharma

Alternative Names: Cutaquig; Gammanorm; IGIM-Octapharma; IGSC-Octapharma; Immune globulin, Subcutaneous (Human)-hipp - Octapharma; Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution - Octapharma; Octanorm

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Octapharma
  • Developer Aarhus Universitetshospital; Octapharma; Rigshospitalet
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Agammaglobulinaemia; Immunodeficiency disorders
  • No development reported Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease
  • Discontinued Dermatomyositis

Most Recent Events

  • 08 Dec 2025 Immune globulin 16.5% is registered for Immunodeficiency disorders in Iceland, Liechtenstein and European Union
  • 18 May 2023 Adverse events data from a phase III trial in Immunodeficiency disorder released by Octapharma
  • 06 Mar 2023 Adverse events data from a phase III trial in Immunodeficiency disorder released by Octapharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top